Literature DB >> 16781179

Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer.

Emmanuelle Coutanceau1, Pierre Legras, Laurent Marsollier, Gilles Reysset, Stewart T Cole, Caroline Demangel.   

Abstract

Buruli ulcer, a disease caused by Mycobacterium ulcerans, is emerging as an increasingly important cause of morbidity throughout the world, for which surgery is the only efficient treatment to date. The aim of this work was to identify potential vaccine candidates in an experimental model of mouse infection. In BALB/c mice infected with M. ulcerans subcutaneously, Hsp65 appeared to be an immunodominant antigen eliciting both humoral and cellular responses. However, vaccination of mice with a DNA vector encoding Mycobacterium leprae Hsp65 only poorly limited the progression of M. ulcerans infection. In contrast, a substantial degree of protection was conferred by subcutaneous vaccination with BCG, suggesting that BCG antigens that are conserved in M. ulcerans, such as TB10.4, the 19 kDa antigen, PstS3 and Hsp70, may be interesting to consider as subunit vaccines in future prospects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781179     DOI: 10.1016/j.micinf.2006.03.009

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  20 in total

1.  Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation.

Authors:  Laure Guenin-Macé; Romain Veyron-Churlet; Maria-Isabel Thoulouze; Guillaume Romet-Lemonne; Hui Hong; Peter F Leadlay; Anne Danckaert; Marie-Thérèse Ruf; Serge Mostowy; Chiara Zurzolo; Philippe Bousso; Fabrice Chrétien; Marie-France Carlier; Caroline Demangel
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

2.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

3.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

4.  A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.

Authors:  Audrey Tanghe; Pierre-Yves Adnet; Tatiana Gartner; Kris Huygen
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

5.  Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

7.  Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics.

Authors:  Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Annick Chauty; Florence Migot-Nabias; Cyril Badaut; Angèle Bénard; Marie-Therese Ruf; Torsten Seemann; Paul D R Johnson; John K Davies; Grant A Jenkin; Gerd Pluschke; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

8.  Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study.

Authors:  Junichiro En; Masamichi Goto; Kazue Nakanaga; Michiyo Higashi; Norihisa Ishii; Hajime Saito; Suguru Yonezawa; Hirofumi Hamada; Pamela L C Small
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

Review 9.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

10.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.